Medicare Enrolled
Dr. Asit Jha, MD
Medical Oncology · Waycross, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jha from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jha?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jha
Dr. Asit Jha is a medical oncology specialist in Waycross, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jha performed 222,022 Medicare services across 4,193 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jha received a total of $5,270 from 51 pharmaceutical and/or device companies across 242 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jha is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in GA
$5,270 industry payments
Medicare Practice Summary
Medicare Utilization ↗222,022
Medicare services
Top 3% in GA for medical oncology
4,193
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~11,101 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
63,750 | $0 | $4 |
| Anti-nausea injection (aprepitant) | 36,010 | $1 | $6 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
31,600 | $0 | $18 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
17,280 | $6 | $25 |
| Denosumab injection (Prolia/Xgeva) | 13,620 | $18 | $63 |
| Pembrolizumab injection (Keytruda) | 11,900 | $43 | $157 |
| Iron infusion (Monoferric) | 11,600 | $16 | $74 |
| Paclitaxel chemotherapy injection | 11,178 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,836 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,452 | $8 | $29 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,180 | $1 | $41 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,342 | $2 | $7 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,276 | $64 | $277 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,270 | $11 | $66 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,095 | $92 | $390 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,003 | $10 | $67 |
| Anti-nausea injection (ondansetron/Zofran) | 984 | $0 | $3 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
936 | $88 | $654 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
886 | $8 | $9 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
873 | $91 | $421 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
521 | $2 | $39 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
364 | $20 | $103 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
290 | $44 | $208 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
274 | $74 | $210 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
255 | $45 | $205 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
220 | $17 | $83 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
205 | $1 | $4 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
195 | $20 | $164 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
171 | $50 | $234 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
151 | $113 | $509 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
150 | $60 | $214 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
88 | $176 | $613 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
87 | $1 | $6 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
80 | $1 | $22 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
78 | $6 | $126 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
74 | $23 | $105 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
72 | $2 | $9 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
67 | $95 | $406 |
| Automated red blood cell count An automated laboratory test that measures the number of red blood cells in a blood sample. |
66 | $4 | $12 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
64 | $3 | $11 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
60 | $14 | $65 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
58 | $132 | $550 |
| New patient office visit, complex (60-74 min) | 55 | $162 | $673 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
50 | $42 | $180 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
46 | $1 | $6 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
41 | $38 | $177 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
34 | $24 | $121 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
30 | $124 | $543 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
27 | $8 | $40 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
27 | $70 | $324 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
15 | $79 | $308 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
13 | $10 | $39 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
12 | $45 | $342 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
11 | $1 | $17 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
34.9% high complexity
61.5% medium
3.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,270
Total received (2018-2024)
Avg $753/year across 7 years
Top 49% in GA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
51
Companies
242
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,180 (60.3%)
Other
Charitable contributions, space rental, and other categories
$1,336 (25.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$755 (14.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$199
2023
$670
2022
$1,936
2021
$1,055
2020
$355
2019
$1,019
2018
$37
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$100
PFIZER INC.
$99
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,352
Amgen Inc.
$354
Genentech USA, Inc.
$295
PFIZER INC.
$295
Janssen Biotech, Inc.
$202
NOVARTIS PHARMACEUTICALS CORPORATION
$167
E.R. Squibb & Sons, L.L.C.
$147
Celgene Corporation
$146
Regeneron Healthcare Solutions, Inc.
$130
Clovis Oncology, Inc.
$127
AstraZeneca Pharmaceuticals LP
$125
Gilead Sciences, Inc.
$122
Seagen Inc.
$117
Astellas Pharma US Inc
$116
GENZYME CORPORATION
$112
Kite Pharma, Inc.
$108
Merck Sharp & Dohme Corporation
$98
Daiichi Sankyo Inc.
$94
Merck Sharp & Dohme LLC
$87
JAZZ PHARMACEUTICALS INC.
$79
G1 Therapeutics, Inc.
$71
Exelixis Inc.
$65
Octapharma USA, Inc.
$64
ABBVIE INC.
$62
Takeda Pharmaceuticals U.S.A., Inc.
$56
Seattle Genetics, Inc.
$50
Taiho Oncology, Inc.
$48
Eisai Inc.
$48
EISAI INC.
$43
Puma Biotechnology, Inc.
$38
GlaxoSmithKline, LLC.
$38
PUMA BIOTECHNOLOGY, INC.
$36
CTI BioPharma Corp.
$32
Karyopharm Therapeutics Inc.
$31
MorphoSys, US Inc.
$30
Teva Pharmaceuticals USA, Inc.
$28
Dova Pharmaceuticals
$28
Boehringer Ingelheim Pharmaceuticals, Inc.
$25
Alexion Pharmaceuticals, Inc.
$21
Vifor Pharma, Inc.
$20
SOBI, INC
$18
Adaptive Biotechnologies Corporation
$18
SANOFI-AVENTIS U.S. LLC
$18
Mirati Therapeutics, Inc.
$17
AbbVie Inc.
$15
Pharmacyclics LLC, An AbbVie Company
$14
EMD Serono, Inc.
$14
Secura Bio, Inc.
$14
Servier Pharmaceuticals LLC
$12
Verastem, Inc.
$12
Lilly USA, LLC
$12
Top 3 companies account for 38.0% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · Alecensa · Avastin · BENDEKA · BLENREP · BOSULIF · Blincyto · CALQUENCE · COSELA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · ERLEADA · Erleada · FARYDAK · FEMARA · GILOTRIF · Gazyva · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · NERLYNX · Nerlynx · Nplate · ONUREG · OPDIVO · PADCEV · PANZYGA · PIQRAY · PROMACTA · REBLOZYL · RYBREVANT · Reblozyl · Rubraca · SCEMBLIX · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TUKYSA · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · Vectibix · Veltassa · Vonjo · XPOVIO · XTANDI · Xospata · Xtandi · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (60%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
1
Per 100K population
2.8
County median income
$44,833
Nearest hospital
Memorial Satilla Health
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jha is a mixed practice specialist, with above-average Medicare volume (top 3% in GA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jha experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Jha performed 63,750 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jha receive payments from pharmaceutical companies?
Yes. Dr. Jha received a total of $5,270 from 51 companies across 242 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jha's costs compare to other medical oncologists in Waycross?
Dr. Jha's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jha) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Waycross
Browse medical oncologists in Waycross ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in GA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in GA
Which GA medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology